Most Read Articles
3 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
3 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 18 Nov 2020
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).

Ruxolitinib cream ineffective against alopecia areata

16 Feb 2020

A 1.5% ruxolitinib cream does not seem to be effective for patients with alopecia areata (AA), a recent phase II study has found.

The present study occurred over two parts. In the first, researchers conducted an open-label, 24-week trial of 1.5% ruxolitinib cream on 12 AA patients with 25–99 percent hair loss, followed by an extension period. The second part was a double-blind, vehicle-controlled study on 78 AA patients with 25–100 percent hair loss. This was followed by a crossover to ruxolitinib by the vehicle group.

In the first part, 25.0 percent (n=3) of the participants achieved at least a 50-percent improvement in the Severity of Alopecia Tool (SALT50) by week 12. Another patient met this endpoint by week 18. By the end of the study at week 24, half of the population (n=6) had met SALT50.  

The extension phase included nine patients, four of whom were at SALT50, and lasted for mean of 57.5 weeks. At week 48, one patient who had SALT50 further improved to SALT90 and another discontinued the study. None of those who were not at SALT50 at the beginning of the extension phase achieved SALT50 by its end.

In the second part, two ruxolitinib patients (5.1 percent) achieved SALT50 as early as week 8 and, by 24 weeks, this number increased to five patients (12.8 percent); over this time period, the same number of vehicle participants achieved SALT50. The between-group difference was nonsignificant (p=0.99).

Sixty-three patients continued on to the open-label period, with 32 crossing over to ruxolitinib cream treatment. Researchers found no statistical impact of the crossover on SALT50 and improvement in SALT scores from baseline.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
3 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 18 Nov 2020
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).